Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06012669 · ClinicalTrials.gov registry record · NA
Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function
A NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT06012669 is a NA study that has completed, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 66 participants.
The verdict
NCT06012669, a NA study, has completed, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of 28-day supplementation with high-dose human recombinant lactoferrin, low-dose human recombinant lactoferrin, and an active control product formulated with bovine lactoferrin on indicators of immunity in healthy males and females.
Interventions
- DIETARY_SUPPLEMENT High dose Human Lactoferrin
- DIETARY_SUPPLEMENT Low dose Human Lactoferrin
- DIETARY_SUPPLEMENT Active Control Bovine Lactoferrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2023-12-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06012669
The ClinicalTrials.gov registry entry for NCT06012669 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midwest Center for Metabolic and Cardiovascular Research, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which High dose Human Lactoferrin is the first listed.
NCT06012669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06012669 about?
NCT06012669 is a clinical study titled "Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function". The purpose of this study is to evaluate the impact of 28-day supplementation with high-dose human recombinant lactoferrin, low-dose human recombinant lactoferrin, and an active control product formulated with bovine lactoferrin on indicators of immunity in healthy males and females.
What is the current status of trial NCT06012669?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2023-09-06. Estimated completion is 2023-12-27.
What interventions are being tested in trial NCT06012669?
The interventions under investigation include: High dose Human Lactoferrin (DIETARY_SUPPLEMENT), Low dose Human Lactoferrin (DIETARY_SUPPLEMENT), Active Control Bovine Lactoferrin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06012669?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.